Recent Updates
Recently added Catalysts

Arrhythmogenic Right Ventricular Cardiomyopathy: two biotech companies racing to a treatment

Cardiovascular & MetabolicOrphan cornerData as of 2026-09-04

Competitors2in the clinic
Median market cap$277Muniverse median $1.20B
Allocated capital$210M$553M competing
Phase 3 or filed00 mid, 2 early
Pure plays0this indication only
Capital rank253/299crowding rank 99

Arrhythmogenic Right Ventricular Cardiomyopathy is a two-horse race: Lexeo Therapeutics (LXEO, $397M) against Tenaya Therapeutics (TNYA, $156M).

A duopoly prices differently from an empty field. Each company is the other's comparable, so a readout from either side repositions both, and $210M of allocated capital sits on the pair.

LXEO carries 72% of the $553M competing here, so the pair is far from evenly matched.

$210M of allocated capital sits in Arrhythmogenic Right Ventricular Cardiomyopathy, ranking it 253rd of 299 indications by the money committed to it.

Companies developing drugs for Arrhythmogenic Right Ventricular Cardiomyopathy 2

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
LXEOLexeo TherapeuticsLX2020Phase 11$397MNo3 31 Dec 2026
TNYATenaya TherapeuticsTN-401Phase 11$156MNo2 31 Dec 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile. LXEO holds 72% of the $553M competing in this indication.

Why Arrhythmogenic Right Ventricular Cardiomyopathy is a orphan corner

A thin field of small caps. Few competitors, none of them large.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Arrhythmogenic Right Ventricular Cardiomyopathy has 2 competitors and a median of $277M.

Cardiovascular & Metabolic

Cardiovascular & Metabolic holds $89.7B of the map's capital, 13.4% of the total, spread across 29 indications and 44 companies. 9 of those indications have more than one company competing.

See every Cardiovascular & Metabolic indication on the map

Related indications in Cardiovascular & Metabolic

Gout1 company · $211M · median $211MUncontestedAnemia Associated With Chronic Kidney Disease1 company · $180M · median $1.6BUncontestedVenous Leg Ulcers1 company · $170M · median $170MUncontestedEnd Stage Renal Disease1 company · $83M · median $166MUncontestedCoronary Artery Disease1 company · $83M · median $166MUncontestedGestational Diabetes1 company · $424M · median $1.3BUncontestedChronic Idiopathic Constipation1 company · $462M · median $924MUncontestedLong Chain Fatty Acid Oxidation Disorders1 company · $488M · median $1.5BUncontested

Arrhythmogenic Right Ventricular Cardiomyopathy pipeline questions

Which biotech companies are developing drugs for Arrhythmogenic Right Ventricular Cardiomyopathy?

Lexeo Therapeutics (LXEO, LX2020, Phase 1); Tenaya Therapeutics (TNYA, TN-401, Phase 1). Those are the 2 US-listed developers in the $100M to $20B market cap band with a clinical-stage programme in Arrhythmogenic Right Ventricular Cardiomyopathy.

How advanced is the Arrhythmogenic Right Ventricular Cardiomyopathy pipeline?

Of the 2 clinical-stage programmes in Arrhythmogenic Right Ventricular Cardiomyopathy, 0 are in Phase 3 or filed, 0 are in mid-stage development and 2 are in early-stage development.

Which company leads the Arrhythmogenic Right Ventricular Cardiomyopathy field?

LXEO is the largest developer in Arrhythmogenic Right Ventricular Cardiomyopathy, holding 72% of the $553M of market capitalisation competing in the indication. The median competitor is worth $277M.

When is the next Arrhythmogenic Right Ventricular Cardiomyopathy catalyst?

The next dated catalyst in Arrhythmogenic Right Ventricular Cardiomyopathy is LXEO on 31 Dec 2026. 2 dated events across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map